NEO
Neogenomics Inc Industrials Services-Testing Laboratories Russell 3000
$17.38Close
$2.2BMarket cap
$7.19 – $19.9152-week range
Late-januaryNext report · estimated
Highlights
Strengths
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
13%
1wk
up 4.8%
price change
1mo
down 5.3%
price change
12-month return
up 79%
market up 11% ·
its own up 58%
F-score
4 / 9
Weak
Altman Z″
1.46
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.7×
price / book
Earnings yield
down 4.8%
EBIT / enterprise value
Cheaper than
31%
of the market · expensive
Revenue growth
up 10%
year on year
EPS growth
—
latest quarter
Sales growth
up 11%
latest quarter · +0 pts
ROE
down 12%
return on equity
Free cash margin
down 3%
-$21.8M FCF
D/E
0.41
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- gross margin narrowed
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
5.1%
$0.89 a day · 2×ATR $15.61
RS
92 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.7×
vs 50-day average
Up/down volume
1.06
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 28, 2026
Last shock
Oct 6, 2026-14% in one session2.3× volumeon results+5% since
Financials
- Gross 43%
- Net -15%
- Free cash -3%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $444.4M | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Gross margin | 42% | 39% | 37% | 41% | 44% | 43% |
| Operating income | -$14.0M | -$118.8M | -$157.6M | -$107.7M | -$92.1M | -$115.9M |
| Net income | $4.2M | -$8.0M | -$144.0M | -$88.0M | -$79.0M | -$108.0M |
| Net margin | 1% | -2% | -28% | -15% | -12% | -15% |
| Earnings per share | $0.04 | -$0.07 | -$1.16 | -$0.70 | -$0.62 | -$0.84 |
| Free cash flow | -$27.6M | -$90.9M | -$96.9M | -$30.7M | -$34.0M | -$21.8M |
| Free cash margin | -6% | -19% | -19% | -5% | -5% | -3% |
| Cash | $228.7M | $316.8M | $263.2M | $342.5M | $367.0M | $159.6M |
| Long-term debt | $171.9M | $533.7M | $535.4M | $538.2M | $340.3M | $341.9M |
| Shareholders' equity | $694.3M | $1.1B | $998.0M | $941.5M | $902.3M | $836.6M |
| Shares outstanding | 112.08m | 124.11m | 126.91m | 127.37m | 128.15m | 128.99m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 28, 2026 | Quarterly ↗ | Sep 30, 2026 | 28d |
| Jul 28, 2026 | Quarterly ↗ | Jun 30, 2026 | 28d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 17, 2026 | Annual ↗ | Dec 31, 2025 | 48d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Jul 29, 2025 | Quarterly ↗ | Jun 30, 2025 | 29d |
| Apr 29, 2025 | Quarterly ↗ | Mar 31, 2025 | 29d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Jul 30, 2024 | Quarterly ↗ | Jun 30, 2024 | 30d |
| Apr 30, 2024 | Quarterly ↗ | Mar 31, 2024 | 30d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results ↗ |
| Oct 5, 2026 | Results · Director or officer change · Charter or bylaws ↗ |
| Aug 11, 2026 | Director or officer change ↗ |
| Jul 28, 2026 | Results ↗ |
| Jul 20, 2026 | Regulation FD · Other events ↗ |
| Jun 25, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 22, 2026 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| Jun 17, 2026 | Other events ↗ |
| Jun 15, 2026 | Other events ↗ |
| May 22, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 28, 2026 | Results ↗ |
| Feb 17, 2026 | Results ↗ |